title: How can we decide on orbital exenteration for second eye in a patient with basal cell carcinoma?
authors.affiliation: Department of Plastic and Reconstructive Surgery, Adnan Menderes University Medical Faculty, Aydin, Turkey. ecopcu@adu.edu.tr
authors.forename: Eray
authors.initials: E
authors.lastname: Copcu
authors.forename: Nazan
authors.initials: N
authors.lastname: Sivrioglu
authors.forename: Caghan
authors.initials: C
authors.lastname: Baytekin
authors.forename: Sule
authors.initials: S
authors.lastname: Er
authors.forename: Banu
authors.initials: B
authors.lastname: Koc
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use; D002280:Basal Cell Carcinoma / Q000601:surgery* / Q000628:therapy; D002610:Cheek; D019583:Dose Fractionation, Radiation; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000601:surgery* / Q000628:therapy; D017233:Orbit Evisceration; D009918:Orbital Neoplasms / Q000601:surgery* / Q000628:therapy; D018579:Patient Selection; D019651:Plastic Surgery Procedures; D012086:Reoperation; D012878:Skin Neoplasms / Q000601:surgery* / Q000628:therapy
chemical_list: D000970:Antineoplastic Agents; D005472:Fluorouracil